DYSPORT 500 UNITES SPEYWOOD

DRUG2 trials

Sponsors

Ipsen Innovation, Ipsen Pharma

Conditions

Upper limb spasticity (ULS) of any aetiology (in US and France) or post- stroke ULS (in Canada)Upper limb spasticity after stroke or traumatic brain injury

Phase 1

An Integrated Phase I/II, Multicentre, Double-Blind, Randomised, Dysport and Placebo Controlled, Dose-Escalation and Dose-Finding Study to Evaluate the Safety and Efficacy of IPN10200 in the treatment of Adult Upper Limb Spasticity Followed by an Open-label Extension Period

RecruitingCTIS2023-507202-14-00

Ipsen InnovationUpper limb spasticity after stroke or traumatic brain injury

Start: 2021-04-29Target: 298Updated: 2026-01-19

Phase 4

A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport®) in Comparison with OnabotulinumtoxinA (Botox®) when Treating Adults with Upper Limb Spasticity

CompletedCTIS2023-509196-16-00

Ipsen PharmaUpper limb spasticity (ULS) of any aetiology (in US and France) or post- stroke ULS (in Canada)

Start: 2021-11-19End: 2025-03-04Target: 50Updated: 2026-01-12